Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Conditions: Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or Less of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Myeloid Sarcoma; Myeloproliferative Neoplasm; Philadelphia Chromosome Positive Interventions: Drug: Cladribine; Drug: Cytarabine; Drug: Dexrazoxane Hydrochloride; Drug: Gemtuzumab Ozogamicin; Drug: Idarubicin Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Heart | Leukemia | Research | Sarcomas